Clinical trial · Interventional
the Effect of Different Drugs and Infusion Ways on Degree of Postoperative Comfort
the Effect of Different Drugs and Infusion Ways on Degree of Comfort for Patients Undergoing Spinal Neoplasm Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To explore the effect of different drugs and infusion ways on degree of postoperative comfort.Patients undergoing spinal neoplasm surgery receive different patient controlled analgesia(PCA) drugs postoperatively,one group is sufentanil,the other is hydromorphone. Then each drug group will be divided into two subgroups according to the infusion way,intravenously,subcutaneously. During the patient controlled analgesia period, patients' degree of comfort,pain score,sleep quality, the degree of side reaction will be recorded.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Analgesia, Patient-Controlled | — | UNRESOLVED | — |
Interventions
Interventions (8)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| intravenous hydromorphone | Drug | — | UNRESOLVED |
| intravenous hydromorphone and dexmedetomidine | Drug | — | UNRESOLVED |
| intravenous sufentanil | Drug | — | UNRESOLVED |
| intravenous sufentanil and dexmedetomidine | Drug | — | UNRESOLVED |
| subcutaneous hydromorphone | Drug | — | UNRESOLVED |
| subcutaneous hydromorphone and dexmedetomidine | Drug | — | UNRESOLVED |
| subcutaneous sufentanil | Drug | — | UNRESOLVED |
| subcutaneous sufentanil and dexmedetomidine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (8)
- type
- EXPERIMENTAL
- label
- sufentanil administration intravenously
- description
- The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9% normal saline (NS).The PCA pump is connected to the hand vein.The parameters were set as background dose 1.5 ml/h, PCA dose 1ml, locking time 15 min.
- interventionNames
- Drug: intravenous sufentanil
- type
- EXPERIMENTAL
- label
- sufentanil administration subcutaneously
- description
- The dose of sufentanil for patient-controlled analgesia is 3.0μg/Kg dissolving in 100ml 0.9%NS.The PCA pump is connected to the deltoid subcutaneously.The parameters were set as background dose 1.5 ml/h, PCA dose 1 ml, locking time 15 min.
- interventionNames
- Drug: subcutaneous sufentanil
- type
- EXPERIMENTAL
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * American Society of Anesthesiologists (ASA) physical status I or II . Exclusion Criteria: * history of severe heart, hepatic or renal disease, * history of chronic pain condition or opioid use, * body mass index (BMI) ≤18 or ≥30 kg/m2, * alcohol or drug abuse, * relevant drug allergy, * inability to properly describe postoperative pain, * inability to use PCA pump.
References
Publications (1)
- DERIVEDWang J, Cui L, Fan L, Wang J. Clinical Effect of Different Drugs and Infusion Techniques for Patient-controlled Analgesia After Spinal Tumor Surgery: A Prospective, Randomized, Controlled Clinical Trial. Clin Ther. 2021 Jun;43(6):1020-1028. doi: 10.1016/j.clinthera.2021.03.019. Epub 2021 May 2. PMID 33952398